Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2017-02-16

AUTHORS

Keiichi Ito

ABSTRACT

The development of tyrosine kinase inhibitors (TKIs) and inhibitors of mammalian target of rapamycin (mTOR) have led to great progress in the treatment of advanced renal cell carcinoma (RCC). However, in most cases, RCC cells eventually develop drug resistance or drug treatments are stopped because of their adverse events (AEs).TKIs that are selective for targeted molecules have potent antitumor effects and produce few side effects are ideal. Although TKIs that inhibit VEGFR signaling have been widely used, treatment strategies that inhibit other pro-angiogenic signaling pathways are also attractive. Furthermore, the PI3K/Akt/mTOR pathway can be inhibited by the widely used inhibitors of mTORC1. Because these agents only inhibit the mTORC1/S6K pathway, and compensatory pathways upregulate HIF, new drugs that inhibit mTOR2 and/or PI3K and/or Akt activity have been developed. In addition to these inhibitors, immune checkpoint inhibitors have shown strong efficacy and reduced toxicity. We expect the number of drugs that are useful for treating RCC will further increase. If we can use drugs that have potent antitumor activity and little toxicity, the prognoses of RCC patients would be further improved.In this chapter, we introduce forthcoming TKIs and PI3K/Akt/mTOR pathway inhibitors, which are potential treatments for RCC. More... »

PAGES

333-349

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-4-431-55531-5_14

DOI

http://dx.doi.org/10.1007/978-4-431-55531-5_14

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1083890873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, 359-8513, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, 359-8513, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Keiichi", 
        "id": "sg:person.0742101353.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742101353.31"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2017-02-16", 
    "datePublishedReg": "2017-02-16", 
    "description": "The development of tyrosine kinase inhibitors (TKIs) and inhibitors of mammalian target of rapamycin (mTOR) have led to great progress in the treatment of advanced renal cell carcinoma (RCC). However, in most cases, RCC cells eventually develop drug resistance or drug treatments are stopped because of their adverse events (AEs).TKIs that are selective for targeted molecules have potent antitumor effects and produce few side effects are ideal. Although TKIs that inhibit VEGFR signaling have been widely used, treatment strategies that inhibit other pro-angiogenic signaling pathways are also attractive. Furthermore, the PI3K/Akt/mTOR pathway can be inhibited by the widely used inhibitors of mTORC1. Because these agents only inhibit the mTORC1/S6K pathway, and compensatory pathways upregulate HIF, new drugs that inhibit mTOR2 and/or PI3K and/or Akt activity have been developed. In addition to these inhibitors, immune checkpoint inhibitors have shown strong efficacy and reduced toxicity. We expect the number of drugs that are useful for treating RCC will further increase. If we can use drugs that have potent antitumor activity and little toxicity, the prognoses of RCC patients would be further improved.In this chapter, we introduce forthcoming TKIs and PI3K/Akt/mTOR pathway inhibitors, which are potential treatments for RCC.", 
    "editor": [
      {
        "familyName": "Oya", 
        "givenName": "Mototsugu", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-4-431-55531-5_14", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-4-431-55530-8", 
        "978-4-431-55531-5"
      ], 
      "name": "Renal Cell Carcinoma", 
      "type": "Book"
    }, 
    "keywords": [
      "renal cell carcinoma", 
      "tyrosine kinase inhibitors", 
      "adverse events", 
      "metastatic renal cell carcinoma (mRCC) therapy", 
      "PI3K/AKT/mTOR pathway inhibitors", 
      "advanced renal cell carcinoma", 
      "AKT/mTOR pathway inhibitors", 
      "PI3K/AKT/mTOR pathway", 
      "immune checkpoint inhibitors", 
      "mTOR pathway inhibitors", 
      "AKT/mTOR pathway", 
      "potent antitumor effects", 
      "renal cell carcinoma therapy", 
      "number of drugs", 
      "checkpoint inhibitors", 
      "potent antitumor activity", 
      "RCC patients", 
      "cell carcinoma", 
      "pro-angiogenic signaling pathways", 
      "treatment strategies", 
      "drug treatment", 
      "S6K pathway", 
      "antitumor effects", 
      "side effects", 
      "potential treatment", 
      "RCC cells", 
      "carcinoma therapy", 
      "mTOR pathway", 
      "pathway inhibitor", 
      "drug resistance", 
      "mammalian target", 
      "kinase inhibitors", 
      "strong efficacy", 
      "K pathway", 
      "antitumor activity", 
      "new drugs", 
      "little toxicity", 
      "PI3K", 
      "compensatory pathways", 
      "drugs", 
      "signaling pathways", 
      "inhibitors", 
      "Akt activity", 
      "treatment", 
      "reduced toxicity", 
      "forthcoming drugs", 
      "toxicity", 
      "pathway", 
      "targeted molecules", 
      "most cases", 
      "prognosis", 
      "patients", 
      "carcinoma", 
      "therapy", 
      "VEGFR", 
      "efficacy", 
      "rapamycin", 
      "HIF", 
      "activity", 
      "mTOR2", 
      "effect", 
      "cells", 
      "agents", 
      "target", 
      "cases", 
      "events", 
      "resistance", 
      "great progress", 
      "addition", 
      "development", 
      "strategies", 
      "number", 
      "progress", 
      "molecules", 
      "chapter"
    ], 
    "name": "Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy", 
    "pagination": "333-349", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1083890873"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-4-431-55531-5_14"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-4-431-55531-5_14", 
      "https://app.dimensions.ai/details/publication/pub.1083890873"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_473.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-4-431-55531-5_14"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55531-5_14'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55531-5_14'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55531-5_14'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-4-431-55531-5_14'


 

This table displays all metadata directly associated to this object as RDF triples.

142 TRIPLES      22 PREDICATES      100 URIs      91 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-4-431-55531-5_14 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 anzsrc-for:11
4 anzsrc-for:1115
5 schema:author N6dc529b6304d44b0afa0207b35ea1843
6 schema:datePublished 2017-02-16
7 schema:datePublishedReg 2017-02-16
8 schema:description The development of tyrosine kinase inhibitors (TKIs) and inhibitors of mammalian target of rapamycin (mTOR) have led to great progress in the treatment of advanced renal cell carcinoma (RCC). However, in most cases, RCC cells eventually develop drug resistance or drug treatments are stopped because of their adverse events (AEs).TKIs that are selective for targeted molecules have potent antitumor effects and produce few side effects are ideal. Although TKIs that inhibit VEGFR signaling have been widely used, treatment strategies that inhibit other pro-angiogenic signaling pathways are also attractive. Furthermore, the PI3K/Akt/mTOR pathway can be inhibited by the widely used inhibitors of mTORC1. Because these agents only inhibit the mTORC1/S6K pathway, and compensatory pathways upregulate HIF, new drugs that inhibit mTOR2 and/or PI3K and/or Akt activity have been developed. In addition to these inhibitors, immune checkpoint inhibitors have shown strong efficacy and reduced toxicity. We expect the number of drugs that are useful for treating RCC will further increase. If we can use drugs that have potent antitumor activity and little toxicity, the prognoses of RCC patients would be further improved.In this chapter, we introduce forthcoming TKIs and PI3K/Akt/mTOR pathway inhibitors, which are potential treatments for RCC.
9 schema:editor Nbec533c72ca24c8a9841cc78a6f7bcfb
10 schema:genre chapter
11 schema:isAccessibleForFree false
12 schema:isPartOf N9a32aab8d01346b4a0d57648f8364157
13 schema:keywords AKT/mTOR pathway
14 AKT/mTOR pathway inhibitors
15 Akt activity
16 HIF
17 K pathway
18 PI3K
19 PI3K/AKT/mTOR pathway
20 PI3K/AKT/mTOR pathway inhibitors
21 RCC cells
22 RCC patients
23 S6K pathway
24 VEGFR
25 activity
26 addition
27 advanced renal cell carcinoma
28 adverse events
29 agents
30 antitumor activity
31 antitumor effects
32 carcinoma
33 carcinoma therapy
34 cases
35 cell carcinoma
36 cells
37 chapter
38 checkpoint inhibitors
39 compensatory pathways
40 development
41 drug resistance
42 drug treatment
43 drugs
44 effect
45 efficacy
46 events
47 forthcoming drugs
48 great progress
49 immune checkpoint inhibitors
50 inhibitors
51 kinase inhibitors
52 little toxicity
53 mTOR pathway
54 mTOR pathway inhibitors
55 mTOR2
56 mammalian target
57 metastatic renal cell carcinoma (mRCC) therapy
58 molecules
59 most cases
60 new drugs
61 number
62 number of drugs
63 pathway
64 pathway inhibitor
65 patients
66 potent antitumor activity
67 potent antitumor effects
68 potential treatment
69 pro-angiogenic signaling pathways
70 prognosis
71 progress
72 rapamycin
73 reduced toxicity
74 renal cell carcinoma
75 renal cell carcinoma therapy
76 resistance
77 side effects
78 signaling pathways
79 strategies
80 strong efficacy
81 target
82 targeted molecules
83 therapy
84 toxicity
85 treatment
86 treatment strategies
87 tyrosine kinase inhibitors
88 schema:name Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy
89 schema:pagination 333-349
90 schema:productId Nc796083cab0e4ae7ab702a7df37d3791
91 Nf6c19a59aa534479ab339810d7ff5283
92 schema:publisher N45643ba5ee234920bf86164ffebdef73
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083890873
94 https://doi.org/10.1007/978-4-431-55531-5_14
95 schema:sdDatePublished 2022-11-24T21:19
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Nae9706e196014bc499a99d3c6978ee18
98 schema:url https://doi.org/10.1007/978-4-431-55531-5_14
99 sgo:license sg:explorer/license/
100 sgo:sdDataset chapters
101 rdf:type schema:Chapter
102 N45643ba5ee234920bf86164ffebdef73 schema:name Springer Nature
103 rdf:type schema:Organisation
104 N6dc529b6304d44b0afa0207b35ea1843 rdf:first sg:person.0742101353.31
105 rdf:rest rdf:nil
106 N9a32aab8d01346b4a0d57648f8364157 schema:isbn 978-4-431-55530-8
107 978-4-431-55531-5
108 schema:name Renal Cell Carcinoma
109 rdf:type schema:Book
110 Nae9706e196014bc499a99d3c6978ee18 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 Nbec533c72ca24c8a9841cc78a6f7bcfb rdf:first Nee443259f44b4da0b8a26784fe5db7c7
113 rdf:rest rdf:nil
114 Nc796083cab0e4ae7ab702a7df37d3791 schema:name doi
115 schema:value 10.1007/978-4-431-55531-5_14
116 rdf:type schema:PropertyValue
117 Nee443259f44b4da0b8a26784fe5db7c7 schema:familyName Oya
118 schema:givenName Mototsugu
119 rdf:type schema:Person
120 Nf6c19a59aa534479ab339810d7ff5283 schema:name dimensions_id
121 schema:value pub.1083890873
122 rdf:type schema:PropertyValue
123 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
124 schema:name Biological Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
127 schema:name Biochemistry and Cell Biology
128 rdf:type schema:DefinedTerm
129 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
130 schema:name Medical and Health Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
133 schema:name Pharmacology and Pharmaceutical Sciences
134 rdf:type schema:DefinedTerm
135 sg:person.0742101353.31 schema:affiliation grid-institutes:grid.416614.0
136 schema:familyName Ito
137 schema:givenName Keiichi
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742101353.31
139 rdf:type schema:Person
140 grid-institutes:grid.416614.0 schema:alternateName Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, 359-8513, Saitama, Japan
141 schema:name Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, 359-8513, Saitama, Japan
142 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...